Investigate / reported ownership
BIIB
Biogen Inc
4 tracked reported owners · snapshot updated 2026-10-04. Delayed disclosures, not live holdings or an investment recommendation.
Who reports owning BIIB?
Select a manager to inspect their portfolio. Reports may cover different quarters; portfolio weights describe disclosed long 13F holdings, not total economic exposure.
| #↑ | Manager | % Port. | History | Value | Shares |
|---|---|---|---|---|---|
| 1 | Joel Greenblatt | 0.1% | 38q | $90M | 418,356 |
| 2 | Samantha McLemore | 2.0% | 10q | $61M | 283,697 |
| 3 | Sarah Ketterer | 0.7% | 8q | $60M | 278,283 |
| 4 | Hillman Capital Management | 3.8% | 27q | $5M | 23,993 |
Go beyond ownership.
Biogen develops and delivers medicines for serious and complex diseases, with a portfolio and pipeline focused on neurological, immunological and rare diseases.
Question to investigate: Can Biogen's pipeline and acquisitions replace revenue from established products that face competitive and pricing pressure?
Company research reviewed 2026-10-02; a dated source-linked starting point, not the investors’ stated reasons.
Understand the business and investment case →Filing dates and original SEC sources
Reported position changes
Net disclosed share changes—not individual trades or execution dates. NEW has no prior-position percentage comparison; EXIT weight refers to the previous report.
| Manager | Move | % Port. | Δ Shares | Value | Filed |
|---|---|---|---|---|---|
| Samantha McLemore | TRIM | 2.0% | -25% | $61M | Aug 13, 2026 |
Keep your next step small.
Save the company and inspect its evidence. Recording a private view is optional and requires a separate, explicit save.
Record my own view →Optional email follow
Latticework Follow
Follow BIIB
Email me only when a reviewed weekly edition contains a material new decision about BIIB: a new position, exit, or a large share-count change that also clears the size threshold. There may be quiet weeks.
Confirm by email. Manage or stop follows in one click. See our privacy notice.
Long US 13F disclosures omit shorts and can be amended. CUSIP 09062X103. No current price, valuation or manager motive is inferred.